Publications

5-year GEMINI extension data confirms Entyvio maintains clinical and endoscopic remission in 60% of moderate-to-severe UC patients with a favorable long-term safety profile. No new safety signals identified.

Systematic review of 28 trials comparing tofacitinib, upadacitinib, and filgotinib against anti-TNF and anti-integrin biologics. JAK inhibitors show faster onset with comparable 1-year remission rates.

Multicenter cohort of 840 UC patients who failed prior anti-TNF therapy. Ustekinumab achieved clinical response in 68% at week 16, with steroid-free remission at 52 weeks in 44%.

Prospective cohort of 3,200 UC patients followed for 3 years. High adherence to Mediterranean dietary patterns was associated with significantly lower rates of hospitalization, steroid use, and endoscopic activity.

Review of 42 studies examining soluble vs. insoluble fiber intake in IBD. Soluble fiber (psyllium, oats) associated with improved mucosal healing; insoluble fiber may exacerbate symptoms during active disease.

Meta-analysis of 19 observational studies (n = 22,000+). High ultra-processed food intake was associated with a 49% increased risk of UC relapse compared to whole-food dietary patterns.

Deep learning model trained on colonoscopy images combined with patient-reported outcome measures enables precision medicine approaches for biologic selection, achieving 82% accuracy in predicting non-response.

Evaluation of smartphone-based symptom tracking in 380 UC patients over 12 months. Patient-reported bowel frequency correlated strongly with endoscopic Mayo sub-scores (r = 0.74, p < 0.001).

UC patients sleeping fewer than 6 hours per night showed 3× higher disease activity scores at follow-up, independent of medication use and stress levels, establishing sleep hygiene as a modifiable risk factor.

392 UC patients in remission followed for 18 months. High perceived stress scores predicted relapse within 6 weeks (HR 2.8, 95% CI 1.9–4.1). Stress-reduction interventions reduced relapse rates by 31%.